NEW YORK, April 23, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to theinvestment community. Today we are offering reports on MYO, NVCN, RMD, and WMGI which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com observes the recent performance of four Medical
Last Friday, shares in Cambridge, Massachusetts headquartered Myomo Inc. ended the session 11.39% higher at $4.01. The stock recorded a trading volume of 2.29 million shares, which was above its three months average volume of 757,990 shares. The Company's shares have advanced 8.09% in the last month and 13.60% in the previous three months. The stock is trading 5.69% above its 50-day moving average. Moreover, shares of Myomo, which provides expanded mobility solutions for patients suffering from neurological disorders and upper limb paralysis in the US, have a Relative Strength Index (RSI) of 62.64. Get the full research report on MYO for free by clicking below at: www.wallstequities.com/registration/?symbol=MYO
Richmond, Canada headquartered Neovasc Inc.'s stock gained 2.08%, to close the day at $0.05 with a total trading volume of 47.87 million shares. The stock is trading 69.84% below their 50-day moving average. Shares of the Company, which develops, manufactures, and markets cardiovascular products worldwide, have an RSI of 32.27.
On April 11th, 2018, Neovasc announced that it has received US$7,132,488 in proceeds from investor-initiated exercises of 4,885,266 of the Series C warrants issued pursuant to the November 2017 underwritten public offering. 10,273,972 Series C Warrants were originally issued in the 2017 Public Transaction, and 5,388,706 remain issued and outstanding at the close of business that day. Gain free access to the research report on NVCN at: www.wallstequities.com/registration/?symbol=NVCN
Shares in San Diego, California headquartered ResMed Inc. recorded a trading volume of 641,569 shares at the close of the last trading session. The stock ended the day 1.56% lower at $98.80. The Company's shares have advanced 0.48% in the last month, 11.41% over the previous three months, and 41.91% over the past year. The stock is trading above its 50-day and 200-day moving averages by 2.73% and 15.72%, respectively. Furthermore, shares of ResMed, which develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases, have an RSI of 54.99.
On April 02nd, 2018, ResMed announced the hire of its first CTO, Bobby Ghoshal, effective that day. As CTO, Ghoshal will lead the Company's global healthcare informatics and data analytics team to drive its cloud-based digital health platforms as well as investments in emerging health technologies, like artificial intelligence and machine learning.
On April 04th, 2018, research firm Citigroup downgraded the Company's stock rating from 'Buy' to 'Neutral'. Signing up today on Wall St. Equities will give you access to the latest report on RMD at: www.wallstequities.com/registration/?symbol=RMD
Wright Medical Group
Amsterdam, the Netherlands headquartered Wright Medical Group N.V.'s shares finished Friday's session 1.63% lower at $19.29. A total volume of 515,864 shares was traded. The stock is trading below its 50-day moving average by 4.37%. Furthermore, shares of Wright Medical, which designs, manufactures, markets, and sells extremities and biologics products, have an RSI of 42.45.
On April 11th, 2018, Wright Medical announced that its operating results for its Q1 ended April 01st, 2018, will be released at 3:00 p.m. CT on May 09th, 2018. The Company will host a conference call at 3:30 p.m. CT to discuss its results. A simultaneous webcast of the call will be available on the Company's corporate website. Register now for today's free coverage on WMGI at: www.wallstequities.com/registration/?symbol=WMGI
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/medical-equipment-stocks-research-reports-released-on-myomo-neovasc-resmed-and-wright-medical-300634292.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Kleine Levin (KLS) or sleeping beauty syndrome is a rare neurological disorder that primarly ...
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...View All